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.2012.11.Abstract Background: Palonosetron is a new, potent, and long-acting 5HT3-receptors antagonist
that had been approved by the FDA for use in postoperative nausea and vomiting (PONV) prophy-
laxis. This study is designed to evaluate its efﬁcacy combined with dexamethasone in PONV pro-
phylaxis in highrisk patients scheduled for laparoscopic surgeries.
Methods: In this double-blind, active-controlled study, 150 patients aged 20–55 years, ASA I–II,
and with Apfel’s PONV score 2–4 were equally randomized to receive dexamethasone 8 mg before
anesthesia induction and saline 30 min before the end of surgery (group D+ S), dexamethasone
8 mg before anesthesia induction and metoclopramide 25 mg 30 min before the end of surgery
(group D +M), or dexamethasone 8 mg combined with palonosetron 0.075 mg before anesthesia
induction and saline 30 min before the end of surgery (group D + P). Incidences of early and late
PONV, complete response, adverse events from antiemetics used, and overall patients’ satisfaction
were recorded.
Results: The incidence of PONV was comparable in the three groups 0–6 h postoperatively. Palo-
nosetron–dexamethasone and dexamethasone–metoclopramide combination therapies signiﬁcantly
reduced the incidence of PONV at 6–12 h postoperatively compared to dexamethasone
monotherapy (12% and 16%, vs. 36%, respectively, with P< 0.05). Moreover, palonosetron–
dexamethasone combination therapy signiﬁcantly reduced the incidence of PONV at 12–24 h post-
operatively compared to both dexamethasone monotherapy (16% vs. 48%, P< 0.01), and
dexamethasone–metoclopramide combination therapy (16% vs. 40%, P< 0.05). The incidenceical Complex, PO Box 946,
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118 E.E. Mansourof adverse drug effects was comparable in the three groups. The overall patients’ satisfaction was
signiﬁcantly higher in palonosetron–dexamethasone combination therapy compared to other
groups.
Conclusion: Palonosetron–dexamethasone combination is effective and safe in PONV (early and
late) prophylaxis in high-risk patients undergoing laparoscopic surgeries with known high-risk of
PONV.
ª 2012 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Postoperative nausea and vomiting (PONV) is often the most
common complication following anesthesia and surgery [1]
with subsequent adverse consequences including delayed
recovery, patient dissatisfaction, unexpected hospital admis-
sion, and delayed return to work [2]. The incidence of PONV
is inﬂuenced by many factors including age, gender, smoking
status, history of PONV or motion sickness, preoperative anx-
iety, type and duration of surgery, volatile anesthetics, nitrous
oxide, postoperative use of opioid analgesics, and ambulation
[1,3–5]. In high-risk patients, the incidence of PONV can reach
up to 80%, indicating the importance of prophylaxis and con-
trol of this distressing complication [6].
Several pharmacological therapies (butyrophenones, anti-
histmincs, and dopamine receptor antagonists) have been tried
in PONV prophylaxis [7,8]. No single antiemetic drug has
proved to be a universal solution to PONV. In general, multi-
modal combination therapy has superior efﬁcacy for PONV
prophylaxis compared with monotherapy [9,10]. Dexametha-
sone was recommended as the ﬁrst line drug, as it is safe and
cheap [11,12]. Metoclopramide had been used as an antiemetic
for more than 40 years (yr) in PONV Prophylaxis, and is
cheap. Because of its triple action (central dopaminergic (D2)
receptors – central and peripheral 5-HT3 receptors peripheral
5-HT4 receptors), it is a potentially interesting drug for PONV
prophylaxis [13].
Palonosetron is the latest potent and selective second gener-
ation 5-HT3 receptor antagonist. It is the only drug of its class
approved for prophylaxis against both acute and delayed che-
motherapy-induced nausea and vomiting (CINV). Far higher
receptor afﬁnity and a much longer half-life (approximately
40 h) than other 5-HT3 antagonists confer a prolonged dura-
tion of action [14,15]. Its use for PONV prophylaxis was ap-
proved by the Food and Drug Administration (FDA) in
March 2008 following successful Phase III clinical trials [2].
The objective of this study is to compare the efﬁcacy of pal-
onosetron combined with dexamethasone vs. dexamethasone
used alone and in combination with metoclopramide as pro-
phylactic regimens for the prevention of PONV after laparo-
scopic surgical procedures with known high-risk of PONV.2. Patients and methods
This study was conducted in the period from April 2012 to
August 2012 at King Fahd Military Medical Complex (Dhahran,
Saudi Arabia) after getting approval of institutional ethical
committee and signed, informed, written consent from each
patient. One hundred and ﬁfty patients, aged 20–55 yr, with
American Society of Anesthesiologists (ASAs) physical statusI or II and scheduled for elective laparoscopic surgical proce-
dures with known high-risk of PONV were included in this
prospective, randomized, double-blind, active-controlled
study. These laparoscopic surgical procedures included chole-
cystectomy, herniorraphy, and gynecological procedures. A
simpliﬁed risk score implemented by Apfel et al. [6] for predict-
ing PONV was used to identify appropriate patients for enroll-
ment in this study. Risk factors were female gender,
nonsmoking status, history of PONV or motion sickness,
and postoperative opioids. Each risk factor was given a score
of one. Only patients who had at least two risk factors (risk
score 2–4) were enrolled. Patients aged > 60 yr, with
ASAP III, their body mass index (BMI)P 35 kg m2, re-
ceived a prophylactic antiemetic within 24 h of surgery, con-
comitant administration of steroids or psychotropic drugs,
having a contraindication to the use of corticosteroids (glau-
coma, severe hypertension, heart disease, renal failure, peptic
ulcer disease, diabetes mellitus, adrenal insufﬁciency, immuno-
suppression, recent tuberculosis), pregnant or lactating wo-
men, had a condition requiring chronic opioid use, or were
allergic to any of the study drugs were excluded and replaced
by other patients.
Patients were randomly allocated into three equal groups
(randomization was performed with the use of sealed enve-
lopes) to receive one of three prophylactic regimens: group
D+ S (dexamethasone + saline group; n= 50), received
intravenous (IV) dexamethasone 8 mg before induction of
anesthesia and placebo (normal saline) 30 min before the ex-
pected end of surgery; group D +M (dexamethasone + met-
oclopramide group; n= 50) received IV dexamethasone 8 mg
before induction of anesthesia and 25 mg metoclopramide IV
30 min before the expected end of surgery; group D + P
(dexamethasone + palonosetron group; n= 50) received
0.075 mg of palonosetron (Emecad) combined with dexa-
methasone 8 mg IV before induction of anesthesia (combina-
tion is known to be physically and chemically compatible)
and saline placebo 30 min before the expected end of surgery.
For proper blinding, the study drugs were prepared by the
operating room (OR) pharmacy in the morning of operation.
They were prepared in two identical 5 ml syringes and labeled;
study drug 1 and 2. Study drug 1 was given immediately before
induction of anesthesia (dexamethasone in groups D + S and
D+M, and combination of dexamethasone and palonosetron
in group D+ P) and study drug 2 was given 30 min before the
expected end of surgery (metoclopramide in group D +M,
and normal saline in groups D + S and D+ P) by the
attending anesthesiologist who was blinded to the study. In
the preoperative visit, all patients were taught to rate the
degree of their perceived preoperative anxiety and pain using
verbal analog scale (VAS). VAS is a verbal numerical rating
scale from 0 to 10 where zero represents one extreme (not
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(anxious as can be, or the worst possible pain). Also, they were
taught to use the patient-controlled analgesia (PCA) pump.
Immediately before surgery, all patients were assessed for
anxiety. The anesthetic technique was standardized for all
patients. Standard monitors were attached namely; 5-leads
electrocardiography (ECG), Pulse oximetry (SpO2), and non-
invasive blood pressure monitor (NIBP). After obtaining
baseline vital signs, the study drug 1 was given slowly IV, then
anesthesia was induced with fentanyl 2 lg kg1 IV and propo-
fol 2–3 mg kg1 IV. Endotracheal intubation was facilitated by
the use of atracurium besylate at a dose of 0.5 mg kg1 IV.
General anesthesia was maintained with sevoﬂurane 2–3% in
oxygen/air mixture (FiO2 = 0.6). 30 min before the expected
end of surgery, study drug 2 was given slowly IV. Immediately
before the end of surgery, sevoﬂurane was discontinued and all
patients were given 1 g paracetamol by IV drip for postopera-
tive analgesia. At time of emergence, residual neuromuscular
block was reversed by 0.05 mg kg1 of neostigmine IV and
0.02 mg kg1 of atropine IV. Anesthesia time (from start of
induction to discontinuation of sevoﬂurane), the time of sur-
gery (from the surgical incision to the placement of surgical
dressings), and recovery times (from discontinuation of sevo-
ﬂurane until the patient can grasp his or her hand on com-
mand) were recorded.
At the postanesthesia care unit (PACU) standard monitors
were connected (ECG–SpO2–NIBP) and all patients were gi-
ven oxygen by face mask at a rate of 4 L min1. The patients
were assessed for pain using VAS and if VAS is >4, rescue
analgesia was given in the form of 1 g paracetamol given by
IV drip and PCA protocol was initiated. The time of nausea
and vomiting episodes were collected from the nursing chart
upon arrival to PACU, at 6, 12 and 24 h postoperatively. Nau-
sea was deﬁned as the subjective sensation of an urge to vomit
with absence of expulsive muscular movements. Vomiting was
deﬁned as forcible expulsion of gastric contents through the
mouth, and retching was deﬁned as an unproductive effort
to vomit. An emetic episode was deﬁned as a single attack of
vomiting or retching, or any number of continuous vomiting
or retches (one emetic episode should be separated from an-
other by an absence of vomiting or retching for at least
1 min). Rescue antiemetic (ondansetron 4 mg IV) was given
if patient experienced continuous nausea for more than
15 min or two or more emetic episodes whilst in hospital.
The treatment was repeated if necessary. Complete response
(CR) of the drug was deﬁned as no PONV and no administra-
tion of rescue antiemetic during the study period.
The PCA device (Graseby 3300 PCA pump, Smiths Group,
UK) was primarily adjusted without background infusion to
deliver a demand dose of 1 ml (10 lg fentanyl) with a lockout
interval of 10 min and, rescue bolus doses of 2 ml (20 lg), and
4-h limit of 200 lg. Those settings could be readjusted accord-
ing to the patient’s VAS in the postoperative period. The total
opioid analgesic consumption was recorded by the acute pain
service nurse in charge who was blinded to the study. Adverse
effects were also recorded including headache, dizziness, myal-
gia, constipation, and extrapyramidal manifestations. At 24 h
postoperatively, the overall patients’ satisfaction with the
PONV prophylactic regimens was assessed using a three-point
scale, in which a score of 1 indicates ‘‘totally dissatisﬁed’’; 2,
‘‘neutral’’; and 3, ‘‘totally satisﬁed’’.The incidence of PONV in laparoscopic surgeries is 75% if
no prophylaxis is given with an anticipated reduction in the
incidence of PONV up to 25% in D+ S group which was
the therapeutic outcome for dexamethasone when given as
the sole prophylactic agent in a previous study established by
power analysis [16]. Based on that, the group size necessary
to detect a clinically relevant difference of 25% in the incidence
of PONV in groups D + P and D+M in relation to the
group D + S was estimated to be 50 patients per group to give
a power of 0.8 at a level of P = 0.05 (a error = 0.05; b
error = 0.1).
Data were presented as mean ± standard deviation (SD),
median (range), or absolute number (percentage) as appropri-
ate. Groups were compared to each other using the parametric
or the nonparametric versions of analysis of variance (ANOVA)
followed by the appropriate post hoc analysis if signiﬁcance
was detected. Nominal data were compared using Chi-square
(v2) test or alternatively by Fisher’s exact test if the expected
frequencies were <5.0. P values <0.05 were considered signif-
icant. Statistical software package (Graph Pad In Stat
version 3.00 for Windows, Graph Pad Software Inc., San
Diego, California, USA) was used for data analysis.3. Results
In this randomized, double-blind, active-controlled study, one
hundred and ﬁfty patients were randomly allocated into three
groups: group D+ S (dexamethasone + saline; n= 50),
group D +M (dexamethasone + metoclopramide; n= 50),
and group D + P (dexamethasone + palonosetron; n= 50).
All patients completed the study.
Groups were comparable with regard to demographic data
(age, gender, BMI, ASA physical status), risk factors for
PONV, and times of anesthesia; recovery; and PACU stay
(Table 1).
Effects of the three antiemetic regimens on PONV are
shown in Table 2. At 0–6 h postoperatively, the incidence of
PONV, rescue antiemetic therapy, and CR was comparable
among the three groups. At 6–12 h postoperatively, the inci-
dence of PONV and rescue antiemetic therapy started to be
signiﬁcantly lower in groups D + P and D+M compared
with the active-control group. Moreover, the number of pa-
tients who showed CR to antiemetic prophylactic therapy
was signiﬁcantly higher in groups D + P and D+M com-
pared with D + S group [44 (88%) and 42 (84%) vs. 32
(64%), respectively, with estimated P value < 0.05] (Table 2).
At 12–24 h postoperatively, the incidence of PONV and rescue
antiemetic therapy was signiﬁcantly lower in D + P group in
comparison with the other two groups (Table 2). Furthermore,
the incidence of CR was signiﬁcantly higher in D + P group in
comparison with D + S, and D+M groups being 84% vs.
52%, and 60%, respectively, with estimated P value < 0.01
for D + S group and P< 0.05 for D +M group (Table 2).
The overall incidence of PONV and rescue antiemetic therapy
over the 24 h study period was signiﬁcantly lower in D + P
group in comparison with other groups (Table 2). Also, the
number of patients who exhibited CR was signiﬁcantly higher
in D + P group in comparison with D + S, and D +M
groups being 42 (84%) vs. 24 (48%), 29 (58%), respectively,
with estimated P value < 0.01 (Table 2).
Table 1 Demographic data, times (anesthesia, surgery, recovery, PACU stay), and risk factors.
Group D+ S (n= 50) Group D+M (n= 50) Group D+ P (n= 50) P value
Age (yr) 33.4 ± 8.6 35.7 ± 9.2 34.9 ± 9.5 0.442
BMI (kg m2) 25.6 ± 6.4 26.9 ± 7.1 27.1 ± 6.2 0.466
ASA class I/II 30/20 23/27 26/24 0.484
Risk factors:
Female gender 29 (58) 23 (46) 28 (56) 0.436
Nonsmoking status 43 (86) 42 (84) 38 (76) 0.387
History of PONV or motion sickness 17 (34) 19 (38) 15 (30) 0.700
Apfel’s risk score: (2/3/4) 6/26/18 4/30/16 7/23/20 0.698
Surgeries performed:
Laparoscopic cholecystectomy 33 (66) 34 (68) 31 (62) 0.814
Laparoscopic hernia repair 8 (16) 6 (12) 7 (14) 0.847
Gynecologic laparoscopy 9 (18) 10 (20) 12 (24) 0.752
Duration of surgery (min) 66.7 ± 13.4 62.6 ± 12.7 65.1 ± 11.9 0.268
Duration of anesthesia (min) 92.6 ± 19.4 99.8 ± 20.2 98.7 ± 21.4 0.166
Recovery time (min) 11.2 ± 3.1 11.8 ± 2.6 11.6 ± 3.4 0.607
PACU stay time (min) 33.2 ± 5.3 34.7 ± 6.2 32.9 ± 5.1 0.225
Preoperative anxiety (VAS) 3.5 (1–5) 3.0 (1–6) 3 (0–6) 0.174
Fentanyl consumption by PCA (mg) 0.46 ± 0.08 0.0.50 ± 0.15 0.49 ± 0.13 0.245
Group D+ S= dexamethasone + saline; group D +M= dexamethasone + metoclopramide; group D + P= dexamethasone + palo-
nosetron; n= number; yr = years; BMI = body mass index; PONV= postoperative nausea and vomiting; PACU= post-anesthesia care
unit; Y/N= yes/no; min = minutes; VAS = visual analog scale; PCA= patient-controlled analgesia; mg = milligrams.
Data are expressed as mean ± SD, median (range), number (percentage), or absolute number.
P< 0.05 was considered signiﬁcant.
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antiemetic regimens, the three groups were comparable (Ta-
ble 3).At the end of the 24 h study period, the number of patients
who were totally satisﬁed with the antiemetic regimens was sig-
niﬁcantly higher in D + P group in comparison with D + S,
and D+M groups being 44 (88%) vs. 24 (48%), and 31
(62%), respectively, with estimated P value < 0.01 (Table 3).4. Discussion
The main ﬁndings in the current study are: (1) Dexamethasone
monotherapy effectively reduced the incidence of early PONV
(0–6 h postoperatively) down to 24% and failed to signiﬁcantly
reduce the incidence of late PONV (6–24 h postoperatively) in
relation to the other two combination therapy groups, (2) Met-
oclopramide–dexamethasone combination therapy effectively
reduced the incidence of PONV 0–12 h postoperatively down
to 16% with signiﬁcant difference at 6–12 h postoperatively in
relation to dexamethasone monotherapy group, and failed in
reducing PONV in the rest of the 24 h study period in relation
to palonosetron–dexamethasone and (3) Only palonosetron–
dexamethasone prophylactic regimen effectively and signiﬁ-
cantly reduced the incidence of PONV over the whole 24 h
postoperative period down to 16% with signiﬁcantly greater
patients’ satisfaction in relation to the other two groups.
PONV is unpleasant and distressing sensation and many
patients consider it to be as debilitating as the pain associated
with surgery [17]. PONV may cause electrolyte disturbances
and may affect the surgical outcome, with unexpected hospital
admission and consequent higher health care costs. PONV is
multifactorial, the important factors being age, sex, smoking
status, history of PONV or motion sickness, type and duration
of surgery, inhalation anesthetics and use of nitrous oxide,postoperative pain, opioid requirements, and inadequate IV
ﬂuid therapy [4,18]. In the current study, all these factors were
considered in patients’ enrollment and only patients with two
or more risk factors (Apfel’s risk score = 2–4) were enrolled
in the study. Additional risk factors were also included as
the type of surgery and only laparoscopic surgeries with
known high-risk of PONV were included namely; cholecystec-
tomy, herniorraphy, and gynecological procedures.
Aspinall and Goodman [19] have suggested that placebo-
controlled trials in patients at high risk of PONV may be
unethical if active drugs are available and for that reason, a
placebo-control group was not included in the current study.
Dexamethasone 8 mg IV, given before induction of anesthesia,
was used instead as an active-control group. The dose of 25 mg
IV of metoclopramide was used in dexamethasone–metoclo-
pramide combination therapy group according to Wallenborn
et al. [13], who concluded in their large multicentric study that
25 mg or 50 mg metoclopramide added to the basic interven-
tion of 8 mg dexamethasone is effective and safe way to pre-
vent PONV. Palonosetron in a dose of 0.075 mg in
palonosetron–dexamethasone combination therapy group
was used according to Kovac et al. [20], who demonstrated
that 0.075 mg of IV palonosetron is the more effective dose
in prevention of PONV than 0.025 mg and 0.05 mg.
Dexamethasone, a long-acting glucocorticoid, has been re-
ported to have an effective prophylactic effect on PONV in
adults undergoing laparoscopic surgery. It has a long biologi-
cal half-life of 36–48 h and excellent side-effects proﬁle after a
single dose of 8 mg IV given before anesthesia induction [21].
The precise mechanism of action is not well understood, but
may be due to prostaglandin antagonism, serotonin inhibition
in the gut and the release of endorphins that elevate mood and
stimulate appetite [22]. In the current study, no difference
observed in prevention of PONV in the early postoperative
Table 2 Incidence of PONV, rescue antiemetic treatment, and complete response.
Time intervals Patients with Group D+ S (n= 50) Group D+M (n= 50) Group D+ P (n= 50) P value
0–6 h Nausea 7 (14) 5 (10) 4 (8) 0.613
Vomiting 6 (12) 4 (8) 2 (4) 0.337
Nausea and vomiting 12 (24) 8 (16) 5 (10) 0.169
Rescue treatment 3 (6) 2 (4) 2 (4) 0.861
Complete response 38 (76) 42 (84) 45 (90) 0.169
6–12 h Nausea 13 (26) 8 (16) 6 (12) 0.172
Vomiting 11(22) 1 (2)** 1 (2)** <0.01
Nausea and vomiting 18 (36) 8 (16)* 6 (12)* <0.01
Rescue treatment 10 (20) 1 (2)** 1(2)** <0.01
Complete response 32 (64) 42 (84)* 44 (88)* <0.01
12–24 h Nausea 17 (34) 12 (24) 6 (12)* 0.034
Vomiting 13 (26) 9 (18) 2 (4)** <0.01
Nausea and vomiting 24 (48) 20 (40) 8 (16)**a <0.01
Rescue treatment 14 (28) 10 (20) 1(2)**a <0.01
Complete response 26 (52) 30 (60) 42 (84)**a <0.01
0–24 h Nausea 21 (42) 18 (36) 8 (16)**a 0.013
Vomiting 16 (32) 10 (20) 2 (4)**a <0.01
Nausea and vomiting 26 (52) 21 (42) 8 (16)**a <0.01
Rescue treatment 15 (30) 12 (24) 2 (4)**b <0.01
Complete response 24 (48) 29 (58) 42 (84)**b <0.01
Group D+ S= dexamethasone + saline; group D+M= dexamethasone + metoclopramide; group D+ P= dex-
amethasone + palonosetron; PONV= postoperative nausea and vomiting; n= number; h = hours.
Data were presented as number (percentage).
* P< 0.05 when compared with the active-control D + S group.
** P< 0.01 when compared with the active-control D + S group.
a P< 0.05 when compared with D +M group.
b P< 0.01 when compared with D +M group.
Postoperative nausea and vomiting prophylaxis 121period (0–6 h) among the three groups and the three regimens
were effective in controlling PONV evidenced by high inci-
dence of CR in the three groups being 76%, 84%, and 90%
in dexamethasone monotherapy, dexamethasone–metoclopra-
mide, and dexamethasone–palonosetron combination thera-
pies, respectively (P= 0.169). The difference was only found
in late postoperative period (6–24 h) and the incidences of
PONV and rescue antiemetic treatment were signiﬁcantly fre-
quent in dexamethasone monotherapy group compared to
the other groups (reaching 36% for PONV and 20% for rescue
treatment at 6–12 h, and 48% for PONV and 28% for rescue
treatment at 12–24 h postoperatively).
Henzi et al. [12] in their systematic review of the prophylac-
tic effect of dexamethasone on PONV concluded that a single
dose of 8 mg dexamethasone is an effective prophylactic anti-
emetic in prevention of early, and late PONV, late efﬁcacy
being most pronounced. These conclusions are consistent with
the ﬁndings in the current study in that the incidence of early
(0–6 h) PONV in dexamethasone monotherapy group was
24% with 51% reduction in the reported incidence of PONV
after laparoscopic surgery as a placebo-control group was
not included in the current study for ethical issues. Further-
more, the incidences of PONV at 6–12 h and 12–24 h postop-
eratively were 36% and 48%, respectively, with 39% and 27%
reductions, respectively, in the reported incidence of PONV
after laparoscopic surgery. Opposite to conclusions of Henzi
et al., late efﬁcacy of dexamethasone was less pronounced
and the higher incidence of PONV for 6–24 h postoperatively
was most likely related to the emetic effect of postoperative
fentanyl and it is evident that combination antiemetic therapywas more effective in controlling this problem. This explana-
tion is supported by a previous study conducted by Apfel
et al. [22] who concluded that postoperative opioid consump-
tion is one of the main predictors of PONV in the late postop-
erative period.
Metoclopramide is still used widely in clinical practice;
however, the dose-responsiveness of metoclopramide in PONV
prophylaxis has never been established [12]. When used in
doses of 10 mg, it was found to be ineffective [23] and larger
dosages were as effective as ondansetron or droperidol when
added to dexamethasone [11]. Metoclopramide in a dose of
50 mg IV has been shown to signiﬁcantly reduce late PONV,
but the side-effects proﬁle is unsatisfactory [13]. Other studies
also found that 20 mg metoclopramide was ineffective, possi-
bly because of the small sample sizes [10,24,25]. The timing
of antiemetic prophylaxis seems to inﬂuence efﬁcacy. In most
of the studies, metoclopramide was given immediately after
induction of anesthesia, irrespective of its time of maximum ef-
fect and short half-life. The results of those previous studies
justify the dose of metoclopramide chosen in the current study
(25 mg IV), and its timing of administration (30 min before the
expected end of surgery) to get the maximal beneﬁcial effect
and avoid its undesirable adverse effects. It was also combined
to the standard IV dexamethasone 8 mg which was given
immediately before anesthesia induction.
Results of the current study revealed that dexamethasone–
metoclopramide combination therapy effectively reduced the
incidence of early (0–6 h) and late (only up to 12 h) PONV
down to 16% compared to 36% incidence in dexamethasone
monotherapy group at 6–12 h postoperatively. However, this
Table 3 Incidence of complications and patients’ satisfaction.
Group D+ S (n= 50) Group D+M (n= 50) Group D+ P (n= 50) P value
Complications
Extrapyramidal symptoms 0 (0) 0 (0) 0 (0) –
Headache 1 (2) 2 (4) 2 (4) 0.813
Dizziness 1 (2) 3 (6) 1 (2) 0.437
Constipation 0 (0) 2 (4) 1 (2) 0.360
Myalgia 1 (2) 3 (6) 2 (4) 0.594
Patients’ satisfaction
Totally satisﬁed 24 (48) 31 (62) 44 (88)**a <0.01
Neutral 2 (4) 7 (14) 4 (8) 0.202
Totally dissatisﬁed 24 (48) 12 (24) 2 (4)**a <0.01
Group D+ S= dexamethasone + saline; group D +M= dexamethasone + metoclopramide; group D + P= dexamethasone + palo-
nosetron; n= number.
Data were presented as number (percentage).
** P< 0.01 when compared with the active-control D + S group.
a P< 0.01 when compared with D +M group.
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dence of PONV at 12–24 h postoperatively being 40% and
was comparable to 46% incidence in dexamethasone mono-
therapy group. This failure may be attributed to the short
half-life of metoclopramide and to the emetic effect of postop-
erative fentanyl given by PCA to control postoperative pain.
The dose of 25 mg metoclopramide was found to be safe evi-
denced by absence of extrapyramidal manifestations and the
incidence of other adverse events was comparable in the three
prophylactic regimens. These results are consistent with the
multicentric study conducted by Wallenborn et al. [13] who
found that 25 mg metoclopramide combined to the standard
8 mg dexamethasone was effective in preventing PONV and
the need for rescue drugs up to 12 h postoperatively with high
safety proﬁle.
Palonosetron had been approved by FDA for PONV pro-
phylaxis in March 2008. Afterward multiple clinical researches
were conducted to prove its efﬁcacy. Candiotti et al. [26] con-
ducted a study in a large series of patients scheduled for outpa-
tient abdominal or gynecological laparoscopy and found that
the incidence of CR from 0 to 24 h was 43%, and nausea sever-
ity was markedly decreased. Similarly, Kovac et al. [20] in their
multicentric study found that 56% of the study population had
CR from 0 to 24 h. Results of the current study revealed that
combination therapy of 0.075 mg palonosetron and 8 mg dexa-
methasone given at the time of anesthesia induction effectively
reduced incidence of PONV and 84% of this study population
had CR from 0 to 24 h postoperatively. This incidence of CR
was signiﬁcantly higher compared with other the regimens
used, being 58% in dexamethasone–metoclopramide combina-
tion and 48% in dexamethasone monotherapy with estimated
P< 0.01.
The higher incidence of CR in palonosetron–dexamethasone
combination therapy group was comparable to the reported
incidences in other studies. Bhattacharjee et al. [27] found the
incidence of CR to be 90% during 0–48 h postoperatively when
palonosetron 0.075 mg was given IV prior to induction of
anesthesia to female patients scheduled for laparoscopic chole-
cystectomy. More recently, Ghosh et al. [28] observed that the
incidence of CR during 0–48 h postoperatively was 83.33% in
palonosetron monotherapy and 86.66% when dexametha-
sone was combined to palonosetron in patients undergoinglaparoscopic cholecystectomy. These ﬁndings support the fact
that palonosetron has prolonged protective effect against
PONV; especially when combined with dexamethasone as it
binds to the allosteric site of 5-HT3 receptors with positive co-
operativity and prevents serotonin from binding to the orthos-
teric site of 5-HT3 receptors [29]. This explains the long half-life
of palonosetron (approximately 40 h) and its high binding afﬁn-
ity for 5-HT3 receptors that is markedly different from older
5-HT3 receptor antagonists. Additionally, there is a cross-talk
between neurokinin-1 (NK-1) and 5HT3 receptors signaling
pathways and substance P (NK-1 receptors agonist) was
shown to potentiate 5-HT3 receptors-mediated inward current.
Palonosetron inhibits the cross-talk between 5-HT3 and NK-1
receptor pathways in dose and time-dependent fashions [30].
The adverse events related to palonosetron administration
were minimal in this study. This observation contributed to
the greatest patients’ satisfaction in palonosetron–dexametha-
sone combination therapy reported in the current study as the
percentage of patients who were totally satisﬁed in that group
was 88% compared to 48% and 62% in dexamethasone mono-
therapy and dexamethasone–metoclopramide combination
therapy groups, respectively (P< 0.01).
In conclusion, palonosetron 0.075 mg when combined with
dexamethasone 8 mg and given immediately before anesthesia
induction is effective and safe regimen in prevention of early
(0–6 h) and late (6–24 h) PONV in high-risk patients scheduled
for laparoscopic surgeries with known high-risk of PONV.
Moreover, palonosetron–dexamethasone combination therapy
is superior to dexamesathone–metoclopramide combination
and dexamethasone monotherapy with regard to the overall
outcome of PONV prophylaxis over 24 h postoperatively, evi-
denced by signiﬁcantly lower incidence of PONV, higher inci-
dence of CR, and greater overall patients’ satisfaction.
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